Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
October 14, 2024 8:33 AM EDT
(Updated - October 14, 2024 8:34 AM EDT)
Stifel analyst Stephen Willey raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $30.00) while maintaining a Buy rating.
The analyst commented: "We like implied risk/reward into the anticipated update of P1/1b NX-5948 data... More
October 14, 2024 7:36 AM EDT
Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $35.00 price target on Nurix (NASDAQ: NRIX).
The analyst commented, "NRIX reported 3Q24 earnings and provided a pipeline update. Most importantly, development of NX-5948 remains on track with two Phase Ia updates expected... More
October 14, 2024 3:50 AM EDT
Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.67), in-line with the analyst estimate of ($0.67). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.98 million.
For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.
...
More
October 11, 2024 5:25 AM EDT
Jefferies analyst Roger Song initiates coverage on Nurix (NASDAQ: NRIX) with a Buy rating and a price target of $41.00.
The analyst said: "NRIX focuses on targeted protein modulation for cancer and I&I. Lead '5948 (BTK degrader) aims to better address broad BTK... More
